MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a multinational bio

OPKO Biologics Ltd., an OPKO Health company (NASDAQ: OPK), today announced that the first participan

KIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (N

Labcorp will purchase Myriad Genetics' prenatal testing business for $210 million in cash, proje

Piper Sandler analyst Edward Tenthoff reiterates OPKO Health (NASDAQ:OPK) with a Overweight and r

OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its

U.S. stocks were mixed; Ladder Capital surged after beating Q3 estimates. Alcoa and other stocks als

U.S. stocks mixed: Dow gained 450+ points, S&P rose, Nasdaq slipped. Healthcare led gains; energ

Labcorp Holdings Inc. (NYSE:LH) stock traded higher Thursday after the company agreed to acquire sel

OPKO Health jumps 18% and Labcorp trades higher as LH acquires BioReference Health assets in an $872

U.S. stocks mixed; Dow up ~200 points. Penske Automotive surged on a $16.3B go-private deal, while O

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO He

Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 28.9% to $4.68 during Thursday's pre-mar

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO He

Acquisition will expand access to clinical laboratory services, including a broad specialty testing

Ardent Health (NYSE: ARDT - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are bot

Shares of OPKO Health, Inc. (NASDAQ: OPK - Get Free Report) have received a consensus recommendation

OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline an

OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships a

OPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while cont

HCA Healthcare (NYSE: HCA - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are bot

MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated health

Connor Clark and Lunn Investment Management Ltd. acquired a new stake in OPKO Health, Inc. (NASDAQ:

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?

OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restruct

OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while reta

OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support,

OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitabili

OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining lo

The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license a

Transaction provides additional non-dilutive capital and enhanced financial flexibility while preser

Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b

Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular se

US stocks trade higher, Dow up 1% on Tuesday. Boeing gains 5% after reporting Q2 results. Kiniksa Ph

U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting bet

Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and

Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market sess

OPKO Health (NASDAQ:OPK) raises FY2026 sales outlook from $530.000 million-$560.000 million to $560.

OPKO Health (NASDAQ:OPK) reported quarterly losses of $(0.01) per share which beat the analyst conse

Gainers Seer (NASDAQ:SEER) stock moved upwards by 33.3% to $2.16 during Thursday's after-market

EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust

OPKO Health, Inc. (NASDAQ:OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (Eir

Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. P

Barrington Research analyst Michael Petusky downgrades OPKO Health (NASDAQ:OPK) from Outperform t

OPKO Health (NASDAQ:OPK) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530

OPKO Health (NASDAQ:OPK) reported quarterly losses of $(0.07) per share which met the analyst consen

ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), today announced that the first partici

Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:OPK) with a Outperform